BioSpace News Archive

Conference Call and Webcast Scheduled for Wednesday, December 11 at 8:00 a.m. EST

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the appointment of Erica Rogers to the company’s board of directors.

Athira Pharma, Inc., a clinical-stage company developing innovative therapies focused on regeneration and recovery of brain function, today announced data from the randomized, placebo-controlled, double-blind Phase 1a/b clinical trial of NDX-1017 in 88 healthy subjects and patients with Alzheimer’s disease that were presented in an oral presentation at the 12th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

Mr. Beck is succeeding Georgia Erbez on the Board of Directors and has been appointed as chair of the audit committee.

FDA removes clinical hold; Company may proceed with VIITAL™ study

Shineco, Inc. announced that its wholly owned subsidiary Tenjove NewHemp Biotech Co., Ltd. has achieved progress in its industrial product system which focuses on cannabidiol development.

Gracell Biotechnologies Co., Ltd (“Gracell”), a clinical-stage immune cell therapy company, today announced the progressive clinical outcomes for leading product candidates FasTCAR-19, Dual CAR-19-22, and Dual CAR-BCMA-19 at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida,

Access to improved Adenocaine™ solution, a ready to administer heart arrest and cardioprotection innovation, is immediately available to hospitals nationwide

Elliott confirms that it has had a multiyear, constructive and private engagement with Alexion that has led to value-creative changes at the Company.

Altasciences has been selected by Indivior PLC to conduct “A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers”, pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose.